OCALA, Fla. — August 15, 2025 — Leads & Copy — AIM ImmunoTech Inc. (NYSE American: AIM) today reported its financial results for the second quarter 2025, highlighting continued progress across pipeline programs with a focus on pancreatic cancer.
A mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS. The company’s bolstered cash position is expected to fund operations for approximately 12 months.
AIM Chief Executive Officer Thomas K. Equels commented that the company continues to prioritize and accelerate development efforts for Ampligen, particularly in the Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca.
Recent highlights include resuming trading on the NYSE American, closing a public equity offering in July raising $8.0 million, and reporting positive data from the Phase 2 DURIPANC clinical study evaluating Ampligen in combination with Imfinzi in metastatic pancreatic cancer patients. The company also announced upcoming presentations at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care.
As of June 30, 2025, AIM reported cash, cash equivalents, and marketable investments of $835,000. Research and development expenses for the three months ended June 30, 2025, were $1.2 million, compared to $1.1 million for the same period in 2024. The net loss from operations for the three months ended June 30, 2025, was $2.8 million, or $(3.68) per share, compared to $1.8 million, or $(3.00) per share, for the three months ended June 30, 2024.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product is Ampligen® (rintatolimod).
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
Source: AIM ImmunoTech Inc.
